VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RDY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RDYDr. Reddy's Laboratories Limited
$14.79$12.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRDYFinancials

Dr. Reddy's Laboratories Limited (RDY) Income Statement

26Y historyFree accessUpdated daily

Revenue contracted 1.7% year-over-year to $86.6B in 2027Q2 while operating margin fell to 13.7% from 23.4% in 2025Q1, reflecting approximately 830 basis points of gross margin compression (60.4% to 52.1%) and negative operating leverage as SG&A held near $27-29B against a shrinking gross profit base.

Income StatementBalance SheetCash FlowRatios

RDY Income Statement

Annual statement

RDY Income Statement

Dr. Reddy's Laboratories Limited (RDY) annual income statement — 26-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01
Sales/Revenue331.38B353.47B325.54B279.16B245.88B214.39B2.56B174.6B153.85B142.03B140.81B154.71B148.19B132.17B116.27B96.74B74.69B70.28B69.44B50.01B65.25B24.33B19.47B20.12B18.02B16.6B10.94B
Revenue Growth %-3.15%8.58%16.61%13.54%14.69%8288.76%-98.54%13.49%8.32%0.87%-8.98%4.4%12.12%13.68%20.19%29.51%6.28%1.2%38.87%-23.36%168.19%24.95%-3.24%11.69%8.51%51.85%-
Cost of Goods Sold167.45B166.95B135.11B115.56B106.54B100.55B1.26B80.59B70.42B65.72B62.45B62.43B62.79B56.37B55.69B43.43B34.43B33.94B32.94B24.6B34.3B12.45B9.39B9.37B7.82B6.86B5.72B
COGS % of Revenue-47.23%41.5%41.39%43.33%46.9%49.22%46.16%45.77%46.28%44.35%40.35%42.37%42.65%47.9%44.9%46.1%48.29%47.44%49.19%52.57%51.17%48.2%46.54%43.38%41.32%52.26%
Gross Profit163.93B186.52B190.43B163.61B139.34B113.84B1.3B94.01B83.43B76.3B78.36B92.28B85.4B75.8B60.58B53.3B40.26B36.34B36.5B25.41B30.95B11.88B10.09B10.76B10.2B9.74B5.22B
Gross Margin %49.47%52.77%58.5%58.61%56.67%53.1%50.78%53.84%54.23%53.72%55.65%59.65%57.63%57.35%52.1%55.1%53.9%51.71%52.56%50.81%47.43%48.83%51.8%53.46%56.62%58.68%47.74%
Gross Profit Growth %--2.05%16.39%17.41%22.4%8671.79%-98.62%12.68%9.34%-2.62%-15.09%8.05%12.67%25.13%13.65%32.39%10.8%-0.44%43.66%-17.9%160.51%17.79%-6.25%5.46%4.71%86.65%-
Operating Expenses134.37B137.65B118.58B95.88B82.2B84.36B866.36M78.02B62.54B64.39B64.86B62.66B59.12B49.77B38.78B34.01B27.64B25.73B25.31B22.05B19.7B10.43B10.45B8.67B6.86B4.68B3.73B
OpEx % of Revenue-38.94%36.43%34.34%33.43%39.35%33.9%44.68%40.65%45.33%46.06%40.5%39.89%37.66%33.35%35.16%37%36.61%36.45%44.1%30.19%42.89%53.68%43.1%38.1%28.2%34.15%
Selling, General & Admin112.14B112.34B93.87B77.2B68.03B62.08B659.9M048.89B46.91B46.37B45.7B42.59B38.78B33.58B28.87B23.69B22.5B21.02B15.18B14.08B8.05B6.81B6.58B5.01B3.66B2.81B
SG&A % of Revenue-31.78%28.84%27.65%27.67%28.96%25.82%-31.78%33.03%32.93%29.54%28.74%29.34%28.89%29.84%31.72%32.02%30.27%30.35%21.59%33.09%34.98%32.68%27.78%22.06%25.69%
Research & Development22.73B25.31B27.38B22.87B19.38B17.48B208.37M15.41B15.61B18.27B19.55B17.83B17.45B12.4B7.67B5.91B5.06B3.79B4.04B3.53B2.47B2.16B2.8B2B1.37B740.85M506.99M
R&D % of Revenue-7.16%8.41%8.19%7.88%8.15%8.15%8.83%10.14%12.86%13.88%11.53%11.77%9.38%6.6%6.11%6.77%5.4%5.81%7.07%3.78%8.87%14.4%9.92%7.61%4.46%4.64%
Other Operating Expenses-1000K0-2.67B-4.2B-5.21B4.8B1.91M62.61B-691M-843M-1.15B-986M-1.06B-1.36B-2.34B-784M-1.11B-569M254M3.34B3.14B226.45M838.82M100.65M488.15M278.38M418.71M
Operating Income29.56B48.87B71.84B67.73B57.14B29.48B431.44M15.99B20.89B11.92B13.5B29.62B26.29B26.03B21.11B18.25B12.63B2.01B-2.83B3.36B11.25B1.45B-366.46M2.08B3.34B5.06B1.49B
Operating Margin %8.92%13.83%22.07%24.26%23.24%13.75%16.88%9.16%13.58%8.39%9.59%19.15%17.74%19.7%18.16%18.87%16.91%2.86%-4.08%6.71%17.24%5.94%-1.88%10.36%18.52%30.48%13.59%
Operating Income Growth %--31.98%6.07%18.52%93.87%6732%-97.3%-23.43%75.28%-11.71%-54.43%12.68%0.98%23.3%15.67%44.54%528.88%170.85%-184.4%-70.16%678.25%494.5%-117.58%-37.52%-34.06%240.61%-
EBITDA51.07B70.55B88.9B82.57B69.78B41.3B13.23B28.46B33.08B23.63B24.77B39.87B34.39B33.14B26.66B23.46B16.78B6.17B980M9.56B14.27B3.02B942.84M3.22B4.35B6.01B2.38B
EBITDA Margin %15.41%19.96%27.31%29.58%28.38%19.26%517.57%16.3%21.5%16.64%17.59%25.77%23.2%25.07%22.93%24.26%22.46%8.78%1.41%19.12%21.87%12.4%4.84%15.98%24.15%36.17%21.75%
EBITDA Growth %-43.53%-20.64%7.67%18.33%68.96%212.23%-53.53%-13.95%40%-4.63%-37.86%15.95%3.77%24.29%13.62%39.87%171.98%529.39%-89.75%-32.98%372.96%219.97%-70.68%-26.1%-27.54%152.52%-
D&A (Non-Cash Add-back)21.51B21.68B17.06B14.84B12.64B11.82B12.8B12.47B12.19B11.71B11.28B10.25B8.1B7.11B5.55B5.21B4.15B4.16B3.81B6.2B3.02B1.57B1.31B1.13B1.01B945.26M892.6M
EBIT32.45B61.61B79.61B73.58B61.8B33.26B362.4M29.31B23.33B15.13B15.29B27.97B29.25B27.88B22.69B19.53B12.68B2.42B-2.33B3.94B11.25B1.45B-289.13M2.08B3.34B5.06B1.49B
Net Interest Income3.22B4.35B-152M567M-248M7M-144M-1.27M-119M-248M-76M573M-31M-189M-118M-690M-127M-123M-1.19B521M0000000
Interest Income7.76B8.28B2.68B2.28B1.18B965M826M12.59M770M540M558M1.4B1.06B1.08B900M377M173M369M482M1.6B0000000
Interest Expense4.53B3.93B2.83B1.71B1.43B958M970M13.86M889M788M634M826M1.09B1.27B1.02B1.07B362M372M1.67B1.08B0000000
Other Income/Expense5.71B8.81B4.94B4.14B3.22B2.82B-75.64M2.04B1.55B2.42B1.16B-2.48B1.88B574M1.41B214M-186M-7.99B-15.44B-493.72M-725.88M446.53M107.4M465.35M572.9M9.11M-426.12M
Pretax Income35.27B57.68B76.78B71.87B60.37B32.3B355.8M18.03B22.44B14.34B14.65B27.14B28.16B26.61B21.68B18.47B12.44B2.05B-4B3.44B10.53B1.89B107.03M2.55B3.92B5.07B1.06B
Pretax Margin %10.64%16.32%23.59%25.74%24.55%15.07%13.92%10.33%14.59%10.1%10.41%17.54%19%20.13%18.64%19.09%16.66%2.92%-5.75%6.88%16.13%7.78%0.55%12.65%21.75%30.53%9.69%
Income Tax7.64B13B19.54B16.19B15.3B8.73B123.59M-1.47B3.65B4.54B2.61B7.13B5.98B5.09B4.9B4.2B1.4B985M1.17B-1.23B1.18B259.07M-94.28M69.41M396.92M153.68M320.24M
Effective Tax Rate %21.66%22.53%25.45%22.52%25.34%27.03%34.74%-8.13%16.25%31.62%17.84%26.26%21.25%19.15%22.6%22.77%11.28%47.98%-29.33%-35.76%11.21%13.69%-88.09%2.73%10.13%3.03%30.22%
Net Income28.03B45.09B56.54B55.68B45.07B23.57B232.21M19.5B18.8B9.81B12.04B20.01B22.18B21.51B16.78B14.26B11.04B1.07B-5.17B4.68B9.35B1.63B211.27M2.48B3.52B4.92B739.28M
Net Margin %8.46%12.76%17.37%19.95%18.33%10.99%9.09%11.17%12.22%6.9%8.55%12.94%14.97%16.28%14.43%14.74%14.78%1.52%-7.44%9.35%14.33%6.71%1.08%12.32%19.55%29.6%6.76%
Net Income Growth %-52.18%-20.26%1.54%23.56%91.22%10049.5%-98.81%3.74%91.67%-18.55%-39.84%-9.77%3.1%28.22%17.63%29.18%933.71%120.67%-210.47%-49.96%472.48%672.98%-91.48%-29.6%-28.35%564.92%-
Net Income (Continuing)27.63B44.68B57.24B55.68B45.07B23.57B232.21M19.5B18.8B9.81B12.04B20.01B22.18B21.51B16.78B14.26B11.04B1.07B-5.17B3.84B9.35B1.63B211.27M2.48B3.52B4.92B739.28M
Discontinued Operations000000000000000000000000000
Minority Interest3.2B3.33B3.78B00000000000192M0000010.5M0000015.92M
EPS (Diluted)33.6453.9267.7766.8054.1728.3420.73117.40113.0959.0172.09116.98129.75126.0498.4483.8164.956.30-30.7022.8058.2110.621.3815.7823.0532.275.85
EPS Growth %-51.64%-20.44%1.45%23.32%91.14%36.71%-82.34%3.81%91.65%-18.14%-38.37%-9.84%2.94%28.04%17.46%29.04%930.95%120.52%-234.65%-60.83%448.12%669.57%-91.25%-31.54%-28.57%451.62%-
EPS (Basic)-53.9267.8566.8054.2928.4220.79117.63113.2859.1372.24117.34130.22126.5298.8284.1665.286.33-30.7022.8858.4610.641.3815.7923.0532.335.85
Diluted Shares Outstanding833.33M833.26M834.3M833.54M831.91M831.69M831.58M830.41M830.98M830.93M834.99M855.36M854.67M853.48M852.16M850.89M849.83M848.08M841.75M843.45M796.28M767.02M765.6M765.5M765.17M761.5M631.78M
Basic Shares Outstanding833.31M832.4M833.31M833.54M830.17M829.41M829.22M828.79M829.58M829.19M833.24M852.74M851.57M850.22M848.89M847.35M845.64M843.53M841.75M840.38M792.76M765.47M765.19M765.14M765.16M760.28M631.78M
Dividend Payout Ratio-15.54%11.78%11.94%11.05%17.59%1785.9%20.08%21.29%40.71%28.16%20.52%13.83%13.88%16.18%15.54%27.74%115.45%-15.76%4.69%26.79%204.3%17.44%5.42%11.41%18.13%

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Structural gross margin erosion in US generics

Growth Deceleration Amid US Pricing Pressure

After posting 95.3% revenue growth in 2025Q2, Dr. Reddy's has decelerated into contraction, with 2027Q2 revenue of $86.6B representing a 1.7% year-over-year decline, suggesting the base portfolio's organic momentum has stalled as new product contributions fail to offset pricing decay.

The trajectory shows a clear deceleration arc: 2025 quarters posted double-digit growth (13.9%-95.3%), which faded to 4.4% by 2026Q3, then turned negative in 2026Q4 (-10.3%) and 2027Q1 (-5.0%). The 95.3% spike in 2025Q2 appears tied to a specific event, likely a limited-competition launch such as a generic or biosimilar franchise, rather than broad-based demand strength, given that subsequent quarters did not sustain that run rate. For a company where North America constitutes 40-50% of revenue, this pattern suggests that either shelf-stock adjustments on earlier launches reversed prior revenue recognition, or US price erosion accelerated beyond the launch cushion. The sequential uptick in 2027Q2 to $86.6B from $81.2B is a modest positive, but the year-over-year comparison still shows contraction, and durability of any recovery depends on the biosimilar pipeline, including Abatacept, ramping as modeled rather than slipping further.

Gross Margin Compression Signals Structural Shift

Dr. Reddy's gross margin has compressed roughly 830 basis points from 60.4% in 2025Q1 to 52.1% in 2027Q2, reflecting a mix shift toward lower-margin commoditized products and unfavorable US pricing dynamics that the company's PSAI integration has not fully insulated against.

The margin deterioration is structural, not cyclical: gross margin declined in seven of the last eight reported quarters, falling from 60.4% to a trough of 44.8% in 2026Q4 before partially recovering to 52.1% in 2027Q2. COGS grew from $30.4B in 2025Q1 to $41.4B in 2027Q2, a 36% increase, while revenue rose only 12.9% over the same span, indicating that input costs, manufacturing overhead, or adverse product mix are outpacing top-line growth. The recent stabilization above 50% could reflect cost discipline or a mix improvement from complex injectables and biosimilars, but the company remains far below the mid-50s-plus margins of 2025-2026, and further erosion appears plausible if US generic pricing continues to reset unfavorably. Investors should note that this compression has occurred despite the vertical integration between PSAI and Global Generics that is typically cited as a margin shield.

Negative Operating Leverage Revealed in SG&A Load

Operating margin has collapsed from 23.4% in 2025Q1 to 13.7% in 2027Q2, as SG&A held near $27-29B against shrinking gross profit, demonstrating that Dr. Reddy's fixed commercial infrastructure has become a meaningful drag on operating leverage during the revenue slowdown.

SG&A spending has been remarkably rigid, ranging between $22.7B and $29.0B across all ten quarters even as gross profit swung between $34.2B and $49.1B. This rigidity means that when gross profit contracts, operating income is hit disproportionately: 2026Q4 saw operating income nearly vanish at $473.2M (0.6% margin) on gross profit of only $34.2B, while comparable SG&A levels in 2025Q4 produced $17.6B of operating income (20.7% margin). R&D spending has been better managed, declining from a $7.3B peak in 2025Q4 to $5.2B in 2027Q2, which partially offsets the SG&A drag and suggests management is actively protecting the earnings line. However, sustained R&D cuts in an innovation-dependent generic franchise risk long-term pipeline replenishment, creating a tension between near-term margin defense and future growth capacity.

EPS Volatility Signals Distorted Earnings Quality

Dr. Reddy's diluted EPS fell 86.0% year-over-year in 2026Q4 to $2.68 and has remained well below 2025 levels, while volatile non-operating items, including stock-based compensation swings from $0 to $113M and likely one-time litigation settlements, further complicate the reliability of reported bottom-line figures.

The earnings quality picture is complicated by several anomalies. Net margin has dropped from 18.1% in 2025Q1 to 10.7% in 2027Q2, a decline that is directionally consistent with operating deterioration, but the quarter-to-quarter EPS volatility is far more extreme than revenue or gross profit variation would suggest, pointing to material non-operating items such as foreign exchange effects, interest income on cash reserves, or litigation settlements. Stock-based compensation has been recorded erratically, at $97M in 2027Q1 but $0 in 2027Q2 and 2026Q4, which may indicate timing-driven recognition rather than true absence of the expense, and investors should treat any quarter with zero SBC as potentially overstating underlying profitability. The Russian and CIS operations, historically a high-margin contributor, could also be introducing currency translation noise that distorts period-over-period comparability. Reported EPS trends should therefore be modeled with caution until non-operating items normalize.

Margin Stabilization Case May Be Premature

The apparent gross margin recovery to 52.1% in 2027Q2 from 44.8% in 2026Q4 may reflect one-time mix or settlement effects rather than durable improvement, as full-year trendlines still show margins roughly 830 basis points below 2025 levels with no structural resolution of US pricing pressure.

The strongest bearish counter-argument is that the 2027Q2 bounce, while superficially encouraging, does not yet establish a new margin regime. The company's operating margin at 13.7% remains 970 basis points below 2025Q1's 23.4%, and revenue is still contracting year-over-year, suggesting that any margin improvement is coming from cost cuts rather than top-line recovery, which is inherently less sustainable. A short-seller would also focus on the risk that gross margin improvements reflect reversals of earlier shelf-stock or sales-return provisions, a known accounting nuance in US generic revenue recognition, rather than genuine pricing stabilization. Combined with a biosimilar pipeline that has yet to demonstrate proven execution and persistent FDA regulatory overhang on key manufacturing sites, the current valuation may be pricing in a margin recovery that the income statement does not yet substantiate.

RDY — Frequently Asked Questions

Quick answers to the most common questions about buying RDY stock.

What was Dr. Reddy's Laboratories Limited's (RDY) revenue in 2026?

For fiscal year 2026, Dr. Reddy's Laboratories Limited (RDY) reported total revenue of $353.47B. This represents a 3132.4% increase compared to $10.94B in 2001.

Is Dr. Reddy's Laboratories Limited (RDY) profitable?

Dr. Reddy's Laboratories Limited (RDY) is profitable, generating $45.09B in net income for the fiscal year ending 2026 with a net profit margin of 12.8%.

What is Dr. Reddy's Laboratories Limited's operating profit margin?

Dr. Reddy's Laboratories Limited (RDY) reported an operating income of $48.87B, resulting in an operating profit margin of 13.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Dr. Reddy's Laboratories Limited's gross profit and gross margin?

Dr. Reddy's Laboratories Limited (RDY) generated $186.52B in gross profit for the year, representing a gross profit margin of 52.8%. This demonstrates the company's core pricing power and production efficiency.